Search

Search Constraints

You searched for: Author/Creator Griguolo, Davide

Search Results

1. AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Issue 7 (24th January 2023)

2. BCR:ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC". (8th October 2022)

3. Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803]. (April 2022)

4. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Issue 6 (20th December 2019)

5. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax. Issue 4 (9th February 2023)

6. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data. Issue 3 (20th April 2020)

7. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. (November 2018)

8. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. (March 2022)